Real-World Efficacy and Safety of Bevacizumab in the First-Line Treatment of Metastatic Cervical Cancer: A Cohort Study in the Total Population of Croatian Patients
Table 1
Characteristics of patients and treatment.
Chemotherapy + bevacizumab (n = 67)
Chemotherapy alone (n = 62)
Age at diagnosis (years), median IQR)
51 (45–60)
56 (46–61)
Menopause, n (%)
45 (67)
38 (61)
Histology, n (%)
Squamous
46 (69)
51 (82)
Adenocarcinoma
16 (24)
7 (11)
Other
5 (8)
4 (6)
ECOG performance status, n (%)a
0
38 (57)
15 (25)
1
24 (36)
29 (48)
2
5 (7)
16 (27)
Body mass index (kg/m2), median (IQR)b
24 (22–29)
24 (22–27)
Previous treatment, n (%)
No therapy before
10 (15)
9 (15)
Surgery alone
10 (15)
1 (2)
Chemoradiotherapy
31 (46)
41 (66)
Surgery + radiotherapy ± chemotherapy
16 (24)
11 (18)
Duration of targeted treatment (months), median (IQR)
4.3 (2.8–8.0)
3.7 (2.0–5.5)
Number of cycles, median (IQR)c
6 (5–11)
6 (3–6)
Follow-up (months), median (IQR)
14.5 (8.6–20.5)
10.9 (3.9–26.4)
IQR = interquartile range (range between the 25th and 75th percentiles). aECOG performance status was missing for 2/62 (3%) patients treated with chemotherapy alone. bBody mass index was missing for 1/67 (1%) patients treated with bevacizumab and for 5/62 (8%) patients treated with chemotherapy alone. cNumber of cycles was missing for 3/62 (5%) patients treated with chemotherapy alone.
